Skip to end of metadata
Go to start of metadata

You are viewing an old version of this page. View the current version.

Compare with Current View Page History

« Previous Version 25 Next »


The TCGA Renal Phenotype Research Group is part of the CIP TCGA Radiology Initiative focused on analyzing images from the TCGA-KIRC collection. Multiple modalities of images which correlate to the kidney renal clear cell carcinoma (KIRC) data in the TCGA Data Portal are currently being gathered for submission to TCIA.

For kidney cancer, TCGA will create a reference genome, against which new patients will be compared, for both clear cell and papillary cancer types. The initial objectives of TCGA for kidney cancer are, according to the NIH:

  • Identify unique patterns of genomic changes that divide clear cell and papillary carcinoma tumors into subgroups
  • Identify genomic differences that distinguish tumors across gender, race or ethnicity
  • Determine if specific patterns of genomic changes are connected to tumor recurrence after therapy

Research and Publications

Data Source


TCGA Data Portal Publication Guidelines

No restrictions; all data available without limitations

TCIA Data Usage Policies and Restrictions

No restrictions; all data available without limitations

Please contact us at if you have any questions about these policies.

TCGA-KIRC Marker Paper and Image Source Sites (ISS)

Imaging Source Site (ISS) Groups will be populated and governed by participants from institutions that have provided imaging data to the archive for a given cancer type. Modeled after TCGA analysis groups, these groups are given the opportunity to publish a marker paper for a given cancer type per the aforementioned publication policy. It is hoped that this will generate increased participation in the building of these multi-institutional data sets that become an open community resource.  Current TCGA-KIRC source sites include:

  • Memorial Sloan-Kettering Cancer Center
  • University of Pittsburgh / UPMC
  • Mayo
  • NCI Urologic Oncology Branch
  • UNC

Please contact Dr. Oguz Akin ( if you have scientific questions you would like to direct to the TCGA-KIRC ISS or are interested in collaborating with their group.


The following links contain publications from the main TCGA project, as well as their posted publication guidelines.

2nd Annual TCGA Symposium

  • Adverse Outcomes in Clear Cell Renal Cell Carcinoma With Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2
    • Ari Hakimi, MD, Memorial Sloan-Kettering Cancer Center
    • Video | Slides
  • TCGA Clear Cell Renal Cell Carcinoma Project
    • Chad J. Creighton, PhD, Baylor College of Medicine
    • Video | Slides
  • No labels